{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-092776","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2025-09-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.041262+00:00","generated_at":"2026-05-17T05:48:14.198973+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences' Phase 3 ZYN002 trial in Fragile X syndrome fails primary endpoint","bullets":["RECONNECT study did not meet primary endpoint of improvement in social avoidance; higher than expected placebo response cited.","Study enrolled 215 patients aged 3 to <30 years; 1:1 randomization to ZYN002 or placebo over 18 weeks.","CEO Jeffrey Dayno reaffirms late-stage pipeline; Phase 3 trials for pitolisant HD in narcolepsy and idiopathic hypersomnia on track for Q4 2025.","Company describes itself as profitable and self-funding biotech with strong cash generation.","Fragile X syndrome has no FDA-approved therapies; company will conduct comprehensive data analysis."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-092776","json":"https://secwatch.observer/filing/0001104659-25-092776.json","markdown":"https://secwatch.observer/filing/0001104659-25-092776.md","text":"https://secwatch.observer/filing/0001104659-25-092776.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000110465925092776/0001104659-25-092776-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000110465925092776/hrmy-20250924x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:48:14.198973+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}